Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Apr 12, 2022 (4 years ago)

Insulin Glargine

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Missing label on the vial

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80

Affected NDC 49502-0393-80

Compare with the code on your package — it is the most precise check available.

Drug: Insulin Category: Diabetes Medication

Recalling firm
Mylan Pharmaceuticals Inc
NDC code
49502-393-80
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0845-2022 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Insulin recalls

See all
Class II · Moderate risk

Myxredlin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0126-12 D-0806-2026
Class II · Moderate risk

Admelog

Lack of Assurance of Sterility: Malformed crimped collar seal

Ongoing Sterility / contamination Sanofi-Aventis U.S. LLC NDC 0024-5926-05 D-0575-2023
Class I · High risk

Insulin Glargine

Labeling: Missing label: Label missing from some prefilled pens.

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-394-71 D-1292-2022
Class I · High risk

Humalog KwikPen

TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.

Completed Temperature excursion Cardinal Health Inc. NDC 0002-8799-59 D-0882-2022

Other recalls by Mylan Pharmaceuticals Inc

All 2022 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026